Suppr超能文献

卵巢癌的临床研究:妇科癌症协作组的共识建议。

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

机构信息

Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium.

Grupo Español de Cáncer de Ovario (GEICO), Madrid, Spain; Clinica Universidad de Navarra, Madrid, Spain; Program for Solid Tumors at Madrid, and Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.

出版信息

Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5.

Abstract

The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.

摘要

妇科癌症协作组(GCIG)第六届卵巢癌临床研究会议于 2021 年 10 月以虚拟形式举行,遵循已发表的共识指南。共识会议的目标是实现卵巢癌即将进行的试验设计要素的协调统一,为未来的研究选择重要问题,并确定未满足的需求。GCIG 的所有 33 个成员组都参与了包括一线治疗、复发性疾病、疾病亚组和未来试验在内的四个卵巢癌临床研究专题组中 20 项声明的制定、完善和通过。20 项声明中有 14 项获得一致同意,其余 6 项声明的一致性超过 90%。GCIG 小组之间的积极审议后获得的高接受率证实,共识过程可以在虚拟环境中应用。这些共识声明与未满足需求的详细分类一起,将促进卵巢癌国际临床研究的协调统一。

相似文献

9
First-line therapy in ovarian cancer trials.卵巢癌临床试验中的一线治疗。
Int J Gynecol Cancer. 2011 May;21(4):756-62. doi: 10.1097/IGC.0b013e31821ce75d.

引用本文的文献

5
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.PARP抑制剂在卵巢癌治疗中的争议与临床未知因素
Ther Adv Med Oncol. 2025 Jun 14;17:17588359251343973. doi: 10.1177/17588359251343973. eCollection 2025.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验